肝动脉化疗栓塞术联合阿帕替尼治疗原发性肝癌的安全性及有效性

Safety and efficacy of hepatic artery transarterial chemoembolization combined with apatinib in the treatment of primary liver cancer

目的分析肝动脉化疗栓塞术(TACE)联合阿帕替尼治疗原发性肝癌的安全性及有效性。方法收集2021年6月至2022年6月收治的72例原发性肝癌患者,随机分为TACE组(采取TACE治疗)和联合组(采取TACE联合阿帕替尼治疗),各36例,比较2组临床疗效。结果治疗后,联合组总胆红素(TBil)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、CD8^(+)水平和不良反应发生率均低于TACE组;CD4^(+)水平、CD4^(+)/CD8^(+)和治疗有效率均高于TACE组,差异具有统计学意义(P<0.05)。结论TACE联合阿帕替尼治疗原发性肝癌,能够显著改善患者的肝功能和免疫功能,治疗有效性较高,且不增加不良反应发生率,具有临床推广价值。

AIM To analyze the safety and efficacy of hepatic artery transarterial chemoembolization(TACE) combined with apatinib in treating primary liver cancer.METHODS A total of 72 patients with primary liver cancer admitted from June 2021 to June 2022 were collected.The study subjects were randomly divided into the TACE group including 36 cases treated with the TACE alone and the combination group including 36 cases treated with the TACE combined with apatinib.The clinical efficacy of 2 groups was compared.RESULTS After treatment,the levels of total bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST),CD8^(+)and the incidence of adverse reactions in combination group were lower than those in the TACE group.The levels of CD4^(+)and CD4^(+)/CD8^(+)in combination group were higher than those in the TACE group.The effective rate of treatment in combination group was higher than that in the TACE group,and the differences were statistically significant(P<0.05).CONCLUSION The TACE combined with apatinib treatment can significantly improve liver function and immune function of patients with high effectiveness and no increase in the incidence of adverse drug reactions,which is valuable for clinical promotion.